PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on innovative treatments for urothelial and specialty cancers, has announced the issuance of inducement restricted stock units (RSUs) to 27 newly hired employees. These grants are part of the company's 2019 Inducement Plan and are aligned with Nasdaq Listing Rule 5635(c)(4), serving as a material inducement for employment with UroGen. The RSUs involve up to 118,000 ordinary shares, which will vest equally over a three-year period, contingent upon the employees' continued service with the company. This initiative is linked to the ongoing commercialization efforts for Jelmyto® and the advancement of UroGen's product pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.